Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
Titel:
Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
Auteur:
Hirsh, V. Park, K. Tan, E.H. Zhang, L. O’Byrne, K. Boyer, M. Yang, J.C.H. Mok, T. Lee, K.H. Lu, S. Shi, Y. Kim, S.W. Laskin, J. Kim, D.W. Laurie, S.A. Kölbeck, K. Fan, J. Dodd, N. Märten, A. Paz-Ares, L.